DVM: small-cap dược liệu with value multiples but execution and liquidity risks
Intrinsic value VND 6,072 vs market VND 5,200 — implied upside 16.8% (model confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược liệu Việt Nam (DVM) is a HNX-listed company operating in the Vietnamese pharmaceutical / herbal medicine segment (ICB: Dược phẩm). Reported revenues were VND 1,450.9 bn in 2025 after a peak of VND 1,580.0 bn in 2024; net profit was VND 40.0 bn in 2025. The company is a small-cap franchise with 47,057,787 shares outstanding and significant founder / individual ownership (largest shareholder 19.99%).
Revenue is concentrated in domestic pharmaceutical and herbal product sales; margins are modest (gross margin 9.6%, EBIT margin 6.3%, net margin 2.8%). Balance-sheet leverage is material (Debt/Equity 1.13) and the firm reports limited free-cash-flow scale (model base FCF VND 943,661,836,007 as an input). Foreign ownership room is closed (foreign_room 0.0), which limits offshore capital flows into the stock.
Luận điểm đầu tư
DVM is trading on traditional value multiples: P/E 6.1x and P/B 0.32x indicate the market prices in low growth and/or execution risk. Our blended intrinsic valuation (70% DCF / 30% PE) yields VND 6,072 per share, implying 16.8% upside to the current match price of VND 5,200. Key valuation drivers include a WACC of 10.0%, terminal growth of 4.0%, and a fair PE of 6.44 used in the PE leg.
However, confidence in the intrinsic estimate is very_low. The model flags low liquidity and very_extreme_upside in its sanity checks; average two-week volume is only 57,000 shares and the stock’s 1-year trading range is VND 4,700–8,700. Operationally, recent revenue has fallen (-8.1% YoY in 2025) and net profit declined to VND 40.0 bn in 2025 from VND 47.9 bn in 2024, suggesting current multiples may reflect real execution issues rather than a pure valuation dislocation.
The core case for owning the stock is valuation upside with limited downside to book value (BVPS VND 16,490.9) and low market multiples; the contra case is that leverage (Debt/Equity 1.13), modest ROE (5.3%) and earnings-quality that is only moderate (58.1/100) may materially constrain upside and raise execution risk. Given the model’s very_low confidence and concentrated insider ownership, potential price gains appear too uncertain to merit a high-conviction position at current levels.
Diễn giải định giá
Blended intrinsic valuation using a 70% DCF and 30% PE blend; DCF uses a 10.0% WACC and 4.0% terminal growth.
- WACC 10.0% (model wacc component), cost of equity ke 10.07% and after-tax cost of debt 5.6%
- Terminal growth rate 4.0% and TV share of value 57.09% (tv_pct 0.5709)
- Base FCF input VND 943,661,836,007 and net debt VND 440,057,626,419
- PE leg uses fair PE 6.44 and PE cap 25 with a 30% weight
- Model blend produced intrinsic VND 6,072 per share with raw_intrinsic_value 241,833.1 and dcf_intrinsic 343,131.5 (model inputs)
The blended intrinsic value implies a 16.8% upside but model confidence is very_low (recalibrated). Key caveats: a large portion of value comes from the terminal and DCF assumptions (wacc 10%, terminal g 4%), and the model’s sanity flags note low liquidity and extreme upside. We therefore treat the VND 6,072 target as a low-confidence reference rather than a precise fair value.
Các luận điểm cần cân nhắc
- Valuation appears inexpensive vs peers: P/E 6.1x and P/B 0.32x with BVPS VND 16,490.9 provide a low base for re-rating.
- Blended model gives intrinsic VND 6,072 — 16.8% upside from VND 5,200 if execution stabilizes.
- EBIT margin of 6.3% and EV/EBITDA 5.9x suggest operating leverage could generate upside if revenue growth resumes.
- Revenue fell -8.1% YoY in 2025 to VND 1,450.9 bn and net profit dropped to VND 40.0 bn, implying persistent execution or demand issues.
- Leverage is meaningful (Debt/Equity 1.13) and net debt (model input) VND 440,057,626,419 reduces financial flexibility.
- Model confidence is very_low with sanity flags for low liquidity; average two-week volume 57,000 shares and foreign ownership room 0.0 constrain market rerating.
- Top shareholder is an individual at 19.99% and overall ownership is concentrated, increasing governance/execution risk.
Bối cảnh ngành
Vietnam’s pharmaceutical and herbal medicines segment is diverse, ranging from large integrated firms to small specialty producers. Regulatory environment and state-controlled channels can materially affect distribution and pricing; VAS accounting differences and inventory/AR recognition policies can cause comparability issues across listed names. Compared with the sector median implied upside of 12.0%, DVM’s 16.8% sits modestly above peers but with far lower liquidity and model confidence.
Peer signals are mixed: several small caps in the peer set show double-digit implied upside while others show deep negatives; DVM’s EV/EBITDA 5.9x and P/S 0.17x place it toward the lower-cost end of the peer group but operational momentum is weak. For SOE-exposed pharma peers, payout mandates and state procurement can provide steadier cash flows — DVM appears more exposed to domestic demand cycles and management execution.
Yếu tố rủi ro
- Operational risk: revenue fell -8.1% in 2025 and net profit declined to VND 40.0 bn, indicating execution or demand weakness.
- Liquidity risk: avg volume 2w of 57,000 shares and HNX listing can result in wide bid-ask spreads and volatile moves; model also flagged low_liquidity.
- Financial risk: Debt/Equity 1.13 with model net debt VND 440,057,626,419 reduces flexibility for capex or M&A buffering.
- Valuation model risk: model confidence is very_low and inputs include a high contribution from terminal value (tv_pct 0.5709).
- Ownership and governance: largest shareholder is an individual at 19.99% and top five holders are concentrated, which can amplify execution or related-party risks.
- Foreign demand constraint: foreign_room 0.0 prevents institutional foreign inflows that might otherwise raise the market multiple.
Yếu tố có thể tác động
- Quarterly / annual results that show a reversal of revenue decline and margin improvement (stabilizing net profit above VND 47.9 bn would be positive).
- Any corporate action that improves liquidity or opens foreign room (placement, listing transfer) could re-rate the multiple.
- Debt reduction or clearer capex / growth plan that reduces Debt/Equity from 1.13 would lower financial risk.
Đánh giá dấu hiệu kế toán
There are no explicit Beneish M-Score data or forensic red flags provided (mscore null and no red_flags). Earnings-quality score is 58.1, which we view as moderate — not a clear sign of manipulation but also not a high-quality earnings signal. Given the absence of forensic alerts, the primary concerns are earnings volatility and concentrated ownership rather than accounting manipulation.
Lịch sử định giá
Model track record over 5 years shows a hit_rate of 0.0 and an average implied upside of 158.35%. The zero hit rate signals that prior model signals have not translated into realized >10% directional calls historically; average upside is inflated by outlier cases. Treat historical model outputs with caution and place greater weight on current fundamentals and liquidity considerations.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-10 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.